All In Biotech

Drug Trial Radar · NCT07701239

A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants

A Study to Evaluate the Relative Bioavailability of SHR-1703 Injection Following Subcutaneous Administration Via a Prefilled Safety Syringe and a Prefilled Autoinjector in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, parallel-group, open-label clinical study designed to compare the bioavailability and safety of SHR-1703 Injection administered subcutaneously using a pre-filled safety syringe (PFS) or a pre-filled autoinjector (AI) in healthy participants. A total of 84 healthy participants are planned to be enrolled and randomized in a 1:1 ratio to either the PFS group or the AI group. Participants in the PFS group will receive a single subcutaneous injection of SHR-1703 Injection using a pre-filled safety syringe, while participants in the AI group will receive a single subcutaneous injection of SHR-1703 Injection using a pre-filled autoinjector.

Conditions

  • Asthma With Eosinophilic Phenotype

Interventions

  • SHR-1703 InjectionDrug

    A single subcutaneous dose of SHR-1703 Injection administered via pre-filled safety syringe.

  • SHR-1703 InjectionDrug

    A single subcutaneous dose of SHR-1703 Injection administered via autoinjector.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. peak concentration (Cmax)Time frame: Days 1-267
  2. area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUC0-t),Time frame: Days 1-267
  3. area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-∞)Time frame: Days 1-267

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital , Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.